AP2218A - Azithromycin dosage forms with reduced side effects - Google Patents
Azithromycin dosage forms with reduced side effectsInfo
- Publication number
- AP2218A AP2218A APAP/P/2004/003145A AP2004003145A AP2218A AP 2218 A AP2218 A AP 2218A AP 2004003145 A AP2004003145 A AP 2004003145A AP 2218 A AP2218 A AP 2218A
- Authority
- AP
- ARIPO
- Prior art keywords
- azithromycin
- alkalizing agent
- effective amount
- dosage form
- glyceryl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708403P | 2003-12-04 | 2003-12-04 | |
PCT/IB2004/001654 WO2005053650A1 (en) | 2003-12-04 | 2004-05-14 | Azithromycin dosage forms with reduced side effects |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2004003145A0 AP2004003145A0 (en) | 2004-09-30 |
AP2218A true AP2218A (en) | 2011-04-20 |
Family
ID=34699855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2004/003145A AP2218A (en) | 2003-12-04 | 2004-05-14 | Azithromycin dosage forms with reduced side effects |
Country Status (8)
Country | Link |
---|---|
CN (1) | CN1697648B (en) |
AP (1) | AP2218A (en) |
AU (1) | AU2004216676B2 (en) |
EC (1) | ECSP045351A (en) |
GT (1) | GT200400183A (en) |
TN (1) | TNSN05319A1 (en) |
UA (1) | UA78793C2 (en) |
ZA (1) | ZA200408075B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200805793B (en) * | 2005-12-22 | 2009-11-25 | Otsuka Pharma Co Ltd | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol |
CN103054813A (en) * | 2012-12-31 | 2013-04-24 | 广东先强药业有限公司 | Azithromycin oral sustained-release dry suspension and preparation method thereof |
CN104177457A (en) * | 2013-05-23 | 2014-12-03 | 长春海悦药业有限公司 | Azithromycin drug raw material, and preparation and application thereof |
CN107427494A (en) * | 2015-03-10 | 2017-12-01 | 卢莫斯制药公司 | The micro- supensoid agent of circular muscle acid |
CA3051914A1 (en) * | 2017-02-02 | 2018-08-09 | Mcmaster University | Bicarbonate as a potentiator for antimicrobial agents |
CN114213484A (en) * | 2021-12-21 | 2022-03-22 | 河北远征药业有限公司 | Tildipirosin 1, 2-propylene glycol solvent compound and preparation method thereof |
CN115212173A (en) * | 2022-07-11 | 2022-10-21 | 上海现代药物制剂工程研究中心有限公司 | Ambroxol hydrochloride spherical sustained-release particles, preparation method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0679400A1 (en) * | 1994-04-29 | 1995-11-02 | Pfizer Inc. | Oral dosage forms of azithromycin avoiding drugfood interaction |
US5633006A (en) * | 1992-07-30 | 1997-05-27 | Pfizer Inc. | Taste-masking composition of bitter pharmaceutical agents |
WO2003063838A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1123279A (en) * | 1995-06-15 | 1996-05-29 | 沈家祥 | Azithmycin water-soluble salt, injection thereof and their usage |
-
2004
- 2004-05-14 AU AU2004216676A patent/AU2004216676B2/en not_active Expired
- 2004-05-14 AP APAP/P/2004/003145A patent/AP2218A/en active
- 2004-05-14 UA UA20041210181A patent/UA78793C2/en unknown
- 2004-05-14 CN CN200480000209.2A patent/CN1697648B/en not_active Expired - Lifetime
- 2004-09-16 GT GT200400183A patent/GT200400183A/en unknown
- 2004-10-06 ZA ZA200408075A patent/ZA200408075B/en unknown
- 2004-10-08 EC ECSP045351 patent/ECSP045351A/en unknown
-
2005
- 2005-12-14 TN TNP2005000319A patent/TNSN05319A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633006A (en) * | 1992-07-30 | 1997-05-27 | Pfizer Inc. | Taste-masking composition of bitter pharmaceutical agents |
EP0679400A1 (en) * | 1994-04-29 | 1995-11-02 | Pfizer Inc. | Oral dosage forms of azithromycin avoiding drugfood interaction |
WO2003063838A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
Also Published As
Publication number | Publication date |
---|---|
CN1697648B (en) | 2010-06-23 |
AU2004216676A1 (en) | 2005-06-23 |
AU2004216676B2 (en) | 2011-06-16 |
ZA200408075B (en) | 2007-01-31 |
AP2004003145A0 (en) | 2004-09-30 |
ECSP045351A (en) | 2005-01-28 |
TNSN05319A1 (en) | 2007-07-10 |
UA78793C2 (en) | 2007-04-25 |
CN1697648A (en) | 2005-11-16 |
GT200400183A (en) | 2005-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200518784A (en) | Azithromycin dosage forms with reduced side effects | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
WO2012079092A3 (en) | Testosterone undecanoate compositions | |
NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
NZ516347A (en) | Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them | |
WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
FR11C0017I1 (en) | ||
EP1708685A4 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
RU2011152105A (en) | COMPOSITIONS OF 3-CYANOCHINOLINE TABLETS AND THEIR APPLICATION | |
NZ532063A (en) | Methods for wet granulating azithromycin | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
MX2007010886A (en) | Acarbose methods and formulations for treating chronic constipation. | |
AP2218A (en) | Azithromycin dosage forms with reduced side effects | |
TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
PL1648473T3 (en) | Single dose fast dissolving azithromycin | |
WO2003105811A3 (en) | Controlled release compositions and methods for using same | |
WO2011108882A3 (en) | Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient | |
NZ595798A (en) | Ectoparasiticidal methods and formulations | |
MD3121F1 (en) | Method of viral hepatitis B prophylaxis | |
RU2002126216A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF LIVER FIBROSIS AND CIRROSIS | |
EP1347754A4 (en) | Compositions for adhesion prevention | |
TW200611686A (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
WO2006036956A3 (en) | Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents | |
GB0224492D0 (en) | Pharmaceutical compositions of rapid drug delivery system to carry active ingredients for fast dissolving tablets by mouth administration |